CA-QUANERGY-SYSTEMS
30.6.2020 15:02:10 CEST | Business Wire | Press release
Quanergy Systems, Inc. , a leading provider of LiDAR (Light Detection and Ranging) sensors and smart perception solutions, today announced the first commercial integration of 3D AI-powered LiDAR solutions with the Genetec Inc. (“Genetec”) Security Center unified security platform. The integrated solutions will provide advanced people flow and occupancy management in smart spaces as well as enhanced threat detection and surveillance in high-security environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630005262/en/
Quanergy’s high-performance AI-powered 3D LiDAR solution will be integrated to the Genetec unified security platform, allowing its use in multiple specialized Security Center modules including Restricted Security Area, Passenger Flow Analytics, and Occupancy Management package to help automate security, people counting and social distancing applications. Adding Quanergy’s 3D LiDAR and sensor data flow to Genetec Security Center provides increased real-time accuracy for a clearer read on actual footfall traffic, occupancy and proximity in a wide variety of industrial applications from transit systems, airports and industrial facilities to public facing businesses including banking and retail.
“Quanergy’s LiDAR flow management solutions bring a new level of real-time 3D insights that make them ideal for any environment where high accuracy and operational intelligence are critical,” said Enzo Signore, CMO at Quanergy. “Our tight integration with the Genetec Security Center unified platform enables a unique level of automation of many applications across retail, critical infrastructure, airport, seaport, enterprise, and smart cities.”
“We are excited to be integrating Quanergy's 3D LiDAR flow management solutions within Genetec Security Center,” said David Lenot, Airport Product Leader at Genetec. “By bringing their 3D LiDAR sensor data into the traffic and passenger flow modules in our unified platform, we’re helping airports and other organizations address pressing needs while also unlocking new insights into their security operations.”
Quanergy’s AI-powered LiDAR solution accurately and reliably monitor wide areas in real-time in a variety of environments without compromising people’s privacy. The new integrated 3D LiDAR-based solutions will provide:
- 98%+ detection accuracy: Quanergy QORTEX People Counter accurately detects the number and direction of people, entering in and out of common areas. This can also be used to detect tailgating and increase the security of critical areas. QORTEX People Counter accuracy is significantly higher than camera-based system.
- Dramatic reduction in false alarms: Quanergy’s QORTEX DTC solution significantly reduces false alarms typical of camera-based systems due to its advanced object detection, tracking, and classification capabilities.
- 5X - 20X lower TCO (total cost of ownership) than camera-based systems due to very wide coverage (360 degree) and long range (40-70m). A single sensor can cover the area upwards of 8000 m2 . This broad area coverage also reduces installation and cabling costs.
- Rich 3D, real-time data: Quanergy’s flow management solutions provide accurate centimeter level information about the number of objects, their spatial location, direction, and speed. Quanergy solutions also can detect distance between people to accurately monitor and manage social distancing policies.
- Privacy protection without compromising or storing private personal information. The LiDAR solutions do not use facial recognition technology nor require opt-in by users; they therefore guarantee the anonymity of people and pose zero PII risk.
- Reliable & Scalable: Works in all lighting and atmospheric conditions so security systems can effectively operate 24/7.
The integrated solutions are available and can be ordered immediately.
For more information, please visit us at www.quanergy.com/contact .
About Quanergy
Quanergy was founded in 2012 and builds on decades of experience of its team in the areas of optics, photonics, optoelectronics, artificial intelligence software and control systems. Headquartered in Sunnyvale, California, in the heart of Silicon Valley, Quanergy offers a high-performance AI-powered LiDAR platform designed to accelerate the automation of key business processes to increase productivity, efficiency, and safety of our 3D world. By providing actionable insights to organizations across major industries including, mapping, security, smart cities and smart spaces, industrial automation and transportation, Quanergy is enabling its partners and their end-users to deploy innovative solutions to drive their business growth and ultimately, improve the quality of life for people around the world. For more information, visit www.quanergy.com .
© Genetec Inc., 2020. Genetec, Security Center and the Genetec logo are trademarks of Genetec Inc. and may be registered or pending registration in several jurisdictions. Other trademarks used in this document may be trademarks of the manufacturers or vendors of the respective product.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005262/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
